NCT04460781View on ClinicalTrials.gov

Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring

CompletedOBSERVATIONAL

Enrollment

96,175

Participants

Timeline

Start Date

September 17, 2018

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions

Influenza

Interventions

BIOLOGICAL

Flublok Quadrivalent influenza vaccine RIV4

Route of administration: Intramuscular

BIOLOGICAL

Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4

Route of administration: Intramuscular

Trial Locations (1)

94612

Kaiser Permanente Northern California, Oakland

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT04460781 - Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring | Biotech Hunter | Biotech Hunter